Medical and Pharmaceutical Statistics Research Unit, Department of Mathematics and Statistics, Lancaster University, Lancashire, UK.
Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
Stat Med. 2018 Dec 20;37(29):4335-4352. doi: 10.1002/sim.7925. Epub 2018 Aug 7.
Population heterogeneity is frequently observed among patients' treatment responses in clinical trials because of various factors such as clinical background, environmental, and genetic factors. Different subpopulations defined by those baseline factors can lead to differences in the benefit or safety profile of a therapeutic intervention. Ignoring heterogeneity between subpopulations can substantially impact on medical practice. One approach to address heterogeneity necessitates designs and analysis of clinical trials with subpopulation selection. Several types of designs have been proposed for different circumstances. In this work, we discuss a class of designs that allow selection of a predefined subgroup. Using the selection based on the maximum test statistics as the worst-case scenario, we then investigate the precision and accuracy of the maximum likelihood estimator at the end of the study via simulations. We find that the required sample size is chiefly determined by the subgroup prevalence and show in simulations that the maximum likelihood estimator for these designs can be substantially biased.
在临床试验中,由于临床背景、环境和遗传等多种因素的影响,患者的治疗反应常常存在异质性。根据这些基线因素定义的不同亚组可能导致治疗干预的获益或安全性特征存在差异。忽略亚组之间的异质性会对医学实践产生重大影响。解决异质性的一种方法是采用具有亚组选择的临床试验设计和分析。针对不同情况已经提出了几种设计类型。在这项工作中,我们讨论了一类允许选择预定义亚组的设计。我们使用基于最大检验统计量的选择作为最坏情况,然后通过模拟研究结束时对最大似然估计的精度和准确性进行了研究。我们发现所需的样本量主要由亚组的流行率决定,并在模拟中表明,这些设计的最大似然估计可能存在较大偏差。